Forecasting The Future: 4 Analyst Projections For GeneDx Holdings
During the last three months, 4 analysts shared their evaluations of GeneDx Holdings (NASDAQ:WGS), revealing diverse outlooks from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 2 | 0 | 1 | 0 | 0 |
| 3M Ago | 0 | 0 | 0 | 0 | 0 |
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $170.0, with a high estimate of $200.00 and a low estimate of $155.00. Surpassing the previous average price target of $155.00, the current average has increased by 9.68%.
Diving into Analyst Ratings: An In-Depth Exploration
An in-depth analysis of recent analyst actions unveils how financial experts perceive GeneDx Holdings. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Brandon Couillard | Wells Fargo | Maintains | Overweight | $155.00 | $155.00 |
| Kyle Mikson | Canaccord Genuity | Raises | Buy | $170.00 | $160.00 |
| Brandon Couillard | Wells Fargo | Raises | Equal-Weight | $155.00 | $140.00 |
| Mark Massaro | BTIG | Raises | Buy | $200.00 | $165.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to GeneDx Holdings. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of GeneDx Holdings compared to the broader market.
- Price Targets: Analysts provide insights into price targets, offering estimates for the future value of GeneDx Holdings's stock. This comparison reveals trends in analysts' expectations over time.
For valuable insights into GeneDx Holdings's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on GeneDx Holdings analyst ratings.
Get to Know GeneDx Holdings Better
GeneDx Holdings Corp delivers personalized and actionable health insights to inform diagnosis, direct treatment and improve drug discovery. The company is uniquely positioned to accelerate the use of genomic and large-scale clinical information to enable precision medicine as the standard of care. The company is at the forefront of transforming healthcare through its various exome and genome testing and interpretation, fueled by one of the world's substantial rare disease data sets.
GeneDx Holdings: A Financial Overview
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Over the 3M period, GeneDx Holdings showcased positive performance, achieving a revenue growth rate of 51.86% as of 30 September, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: GeneDx Holdings's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -6.54%, the company may face hurdles in effective cost management.
Return on Equity (ROE): GeneDx Holdings's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -2.68%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): GeneDx Holdings's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -1.59%, the company may face hurdles in achieving optimal financial returns.
Debt Management: With a below-average debt-to-equity ratio of 0.39, GeneDx Holdings adopts a prudent financial strategy, indicating a balanced approach to debt management.
What Are Analyst Ratings?
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.